- /
- Supported exchanges
- / US
- / CNTA.NASDAQ
Centessa Pharmaceuticals PLC ADR (CNTA NASDAQ) stock market data APIs
Centessa Pharmaceuticals PLC ADR Financial Data Overview
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Centessa Pharmaceuticals PLC ADR (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Centessa Pharmaceuticals PLC ADR data using free add-ons & libraries
Get Centessa Pharmaceuticals PLC ADR Fundamental Data
Centessa Pharmaceuticals PLC ADR Fundamental data includes:
- Net Revenue: 15 000 K
- EBITDA: -213 490 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-17
- EPS/Forecast: -0.3884
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Centessa Pharmaceuticals PLC ADR News
New
Why Centessa Pharmaceuticals (CNTA) Raised $250 Million and What It Means for Its R&D Ambitions
Centessa Pharmaceuticals recently completed a follow-on equity offering, raising approximately US$250 million by issuing over 11.6 million American Depositary Shares at US$21.50 each, with a discount ...
Centessa (CNTA) Hits All-Time High on New $287-Million Fundraising Program
We recently published Market Beaters: 10 Stocks Defying the Odds. Centessa Pharmaceuticals plc (NASDAQ:CNTA) is one of the best-performing stocks on Wednesday. Centessa soared to a new all-time high ...
Why Centessa Pharmaceuticals Stock Crushed the Market Today
Key Points It's gearing up to take in a flood of fresh capital. This is being effected in a secondary issue of its ADSes. 10 stocks we like better than Centessa Pharmaceuticals Plc › U.K.-headquar...
Sector Update: Health Care Stocks Rise Late Afternoon
Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 1.6% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.